The company is a national key high-tech enterprise integrating drug R&D, production and sales, and an A-share listed company on the Shenzhen Stock Exchange. The company is a comprehensive pharmaceutical enterprise integrating drug research and development, production and sales. The business format covers the pharmaceutical industry, pharmaceutical commerce and pharmaceutical retail. The main products are Widimexide (aluminum magnesium carbonate tablets), Nagamatsu (polyethylene glycol 4000 dispersion), diarrheal tablets, choleretic softgels, gabelate mesylate for injection, omeprazole sodium for injection, tangerine tablets, supernatant softgels, hexaviramine capsules, Rongtong (sodium ferulate for injection), cilostazol tablets, captopril tablets, water king (spirulina capsules), ortezomane (injectable sodium hydrochloride) Zine capsules), orlistat capsules. Over the years, the company has successively won many honors such as “National Enterprise Technology Center”, “Healthy China Quality Award”, “China Patent Award”, “2019 China's Top 100 Non-prescription Pharmaceutical Enterprises”, “Pharmaceutical Industry Benchmark Enterprise 70th Anniversary of the Founding of New China”, “National Contract-abiding and Credit-worthy Enterprise”, and “National Intellectual Property Demonstration Enterprise”, and has set up postdoctoral research workstations.
No Data